A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T
Clinical Trial Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Moderna Therapeutics, Inc.
Start Date
February 27, 2020
End Date
September 1, 2020
Administered By
Duke Human Vaccine Institute
Awarded By
Moderna Therapeutics, Inc.
Start Date
February 27, 2020
End Date
September 1, 2020